EMILY MAUL: Open Payments
NPI 1649758475 · LANCASTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$672 in 32 payments from 8 companies in 2025. Trend: 2023 $21 · 2024 $603 · 2025 $672
Food & beverage: $638Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $227 |
| GlaxoSmithKline, LLC. | 8 | $146 |
| Novartis Pharmaceuticals Corporation | 5 | $100 |
| Amgen Inc. | 4 | $90 |
| GENZYME CORPORATION | 1 | $38 |
| PFIZER INC. | 1 | $27 |
| Pharming Healthcare, Inc. | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
Products named: TEZSPIRE, FASENRA, NUCALA, TRELEGY ELLIPTA, AYVAKIT, XOLAIR, PANZYGA, RUCONEST.
Industry payments across PA — which companies pay providers there.
